Deutsche Bank AG Grows Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Deutsche Bank AG boosted its position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 63.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 61,989 shares of the company’s stock after buying an additional 24,170 shares during the quarter. Deutsche Bank AG owned approximately 0.07% of Aquestive Therapeutics worth $221,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of AQST. D. E. Shaw & Co. Inc. boosted its holdings in shares of Aquestive Therapeutics by 307.3% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 126,464 shares of the company’s stock worth $450,000 after acquiring an additional 95,418 shares during the period. Bank of America Corp DE boosted its holdings in shares of Aquestive Therapeutics by 905.2% in the fourth quarter. Bank of America Corp DE now owns 690,284 shares of the company’s stock worth $2,457,000 after acquiring an additional 621,614 shares during the period. Ancora Advisors LLC boosted its holdings in shares of Aquestive Therapeutics by 36.5% in the fourth quarter. Ancora Advisors LLC now owns 28,997 shares of the company’s stock worth $103,000 after acquiring an additional 7,751 shares during the period. Northern Trust Corp boosted its holdings in shares of Aquestive Therapeutics by 3.1% in the fourth quarter. Northern Trust Corp now owns 599,812 shares of the company’s stock worth $2,135,000 after acquiring an additional 18,199 shares during the period. Finally, Aquatic Capital Management LLC boosted its holdings in shares of Aquestive Therapeutics by 400.9% in the fourth quarter. Aquatic Capital Management LLC now owns 62,612 shares of the company’s stock worth $223,000 after acquiring an additional 50,112 shares during the period. 32.45% of the stock is owned by hedge funds and other institutional investors.

Aquestive Therapeutics Stock Performance

NASDAQ:AQST opened at $2.81 on Tuesday. The firm has a market capitalization of $279.11 million, a price-to-earnings ratio of -6.24 and a beta of 2.02. Aquestive Therapeutics, Inc. has a 52-week low of $2.12 and a 52-week high of $5.80. The stock has a fifty day moving average of $2.65 and a 200 day moving average of $3.15.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.07). The company had revenue of $8.72 million during the quarter, compared to the consensus estimate of $12.23 million. Equities analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a report on Thursday, May 15th. Lake Street Capital cut their price target on Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a report on Friday, March 7th. Alliance Global Partners reaffirmed a “buy” rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. Raymond James set a $7.00 price target on Aquestive Therapeutics in a report on Friday, March 7th. Finally, Oppenheimer assumed coverage on Aquestive Therapeutics in a report on Monday. They issued an “outperform” rating and a $7.00 price target for the company. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $10.14.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.